# US 2024/0189404 A1 · Immunogenic peptides with extended oxidoreductase motifs > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2024/0189404 A1 - Document ID: US20240189404A1 - Status: Published application - Kind: A1 - Application number: 17/923,117 - Filed: 2021-05-06 - Published: 2024-06-13 - Earliest claimed: 2020-05-06 - Assignees: Imcyse SA - Applicants: Imcyse SA - Inventors: Milos ERAK - Web page: https://patentgrep.com/patent/US20240189404A1 ## CPC - A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance} - A61K 39/001111: {Immunoglobulin superfamily} - A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - C07K 14/33: from Clostridium (G) - C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens} - C07K 14/70539: {MHC-molecules, e.g. HLA-molecules} - C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]} - C12N 9/0004: {Oxidoreductases (1.)} - A61K 2039/572: {cytotoxic response} - A61K 2039/6031: {Proteins} - C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The invention relates to immunogenic peptides comprising MHC class II T-cell epitopes and oxidoreductase motifs with increased activity, and their use in regulating the immune response in subjects. ## Claims ### Claim 1 An immunogenic peptide, said immunogenic peptide comprising: a) an oxidoreductase motif, b) an MHC class II T-cell epitope of an antigenic protein, and c) a linker between a) and b) of between 0 and 7 amino acids, wherein said oxidoreductase motif has the following sequence: Z(B)n[CST]XmC- or Z(B)nCXm[CST]-; wherein Z is any amino acid or non-natural amino acid, excluding basic amino acids comprising R (Arginine), K (Lysine) and H (Histidine), and excluding amino acids D (Aspartate), W (Tryptophane), E (Glutamate), and A (Alanine); wherein (B) is any amino acid; wherein n is an integer of 0 to 2; wherein Cis Cysteine, S is Serine and T is Threonine; wherein X is any amino acid; wherein m is 2, 0, 1, or 3; and wherein the hyphen (-) in said oxidoreductase motif indicates the point of attachment of the oxidoreductase motif to the N-terminal end of the linker (c) or the epitope (b), or to the C-terminal end of the linker (c) or the epitope (b). ### Claim 2 (depends on 1) The immunogenic peptide according to claim 1, wherein Z is selected from the group consisting of: G (Glycine), S, T, C, V (Valine), L (Leucine), I (Isoleucine), M (Methionine), P (Proline), F (Phenylalanine), Y (Tyrosine), N (Asparagine), and Q (Glutamine). ### Claim 3 (depends on 1) The immunogenic peptide according to claim 1, wherein Z is selected from the group consisting of amino acids: G (Glycine), and P (Proline). ### Claim 4 (depends on 1) The immunogenic peptide according to claim 1, wherein m is 2. ### Claim 5 (depends on 1) The immunogenic peptide according to claim 1, wherein X is any amino acid excluding C, S, and T. ### Claim 6 (depends on 1) The immunogenic peptide according to claim 1, wherein one or more X is a basic amino acid selected from the group consisting of R, K and H. ### Claim 7 (canceled) ### Claim 8 (depends on 1) The immunogenic peptide according to claim 1, wherein said epitope has a length of between 9 and 30 amino acids. ### Claim 9 (depends on 1) The immunogenic peptide according to claim 1, having a length of between 12 and 50 amino acids. ### Claim 10 (depends on 1) The immunogenic peptide according to claim 1, wherein said antigenic protein is an auto-antigen, a soluble allofactor, an alloantigen shed by the graft, an antigen of an intracellular pathogen, an antigen of a viral vector used for gene therapy or gene vaccination, a tumor-associated antigen or an allergen. ### Claim 11 (depends on 1) The immunogenic peptide according to claim 1, wherein the linker is of between 0 and 4 amino acids. ### Claim 12 (depends on 1) The immunogenic peptide according to claim 1, wherein said oxidoreductase motif does not naturally occur within a region of 11 amino acids N-terminally or C-terminally of the MHC class II T-cell epitope in said antigenic protein. ### Claim 13 (depends on 1) The immunogenic peptide according to claim 1, wherein the MHC class II T-cell epitope does not naturally comprise said oxidoreductase motif. ### Claim 14 (depends on 1) The immunogenic peptide according to claim 1, wherein at least one X in the oxidoreductase motif is P (proline) or Y (Tyrosine). ### Claim at position 15 15-17. (canceled) ### Claim 18 (depends on 1) A polynucleotide encoding the immunogenic peptide according to claim 1. ### Claim at position 17 19-22. (canceled) ### Claim 23 (depends on 1) A method for preparing an immunogenic peptide according to claim 1, comprising the steps of: (a) providing a peptide sequence consisting of an MHC class II T-cell epitope of said antigenic protein, and (b) linking to said peptide sequence the oxidoreductase motif, such that said motif and said epitope are either adjacent to each other or separated by a linker of at most 7 amino acids. ### Claim 24 (depends on 1) A method for obtaining a population of antigen-specific cytolytic CD4+ T cells, against APC presenting said antigen, the method comprising the steps of: providing peripheral blood cells; contacting said cells with an immunogenic peptide according to claim 1, or with a polynucleotide encoding such an immunogenic peptide; and expanding said cells in the presence of IL-2. ### Claim 25 (depends on 1) A method for obtaining a population of antigen-specific cytolytic CD4+ T cells, against APC presenting said antigen, the method comprising the steps of: providing an immunogenic peptide according to claim 1 or with a polynucleotide encoding such an immunogenic peptide; administering said peptide or polynucleotide to a subject; and obtaining said population of antigen-specific cytolytic CD4+ T cells from said subject. ### Claim 26 (depends on 24) A population of antigen-specific cytolytic CD4+ T cells obtained by the method of claim 24. ### Claim 27 (depends on 1) A method of treating an autoimmune disease, an infection with an intracellular pathogen, a tumor, an allograft rejection, or an immune response to a soluble allofactors, to an allergen exposure or to a viral vector used for gene therapy or gene vaccination in an individual, comprising administering the immunogenic peptide according to claim 1, or a polynucleotide encoding the immunogenic peptide according to claim 1 to said individual. ### Claim 28 (depends on 1) A method of treating an autoimmune disease, an infection with an intracellular pathogen, a tumor, an allograft rejection, or an immune response to a soluble allofactors, to an allergen exposure or to a viral vector used for gene therapy or gene vaccination in an individual, comprising the steps of: providing peripheral blood cells of said individual, contacting said cells with an immunogenic peptide according to any of claim 1 or with a polynucleotide encoding the immunogenic peptide of claim 1, expanding said cells, and administering said expanded cells to said individual.